New advisory committee will uphold and strengthen Fujifilm’s commitment as a life sciences and healthcare leader to bioethical principles and standards in all areas of its life sciences- and healthcare-related research and business activities in the Americas
VALHALLA, N.Y., November 17, 2025 – FUJIFILMHoldings America Corporation, the regional headquarters of FUJIFILM Corporation — a global leader in life sciences and healthcare — today announced the formation of its Bioethics Advisory Committee, a cross-disciplinary body established to provide independent recommendations, governance guidance, and accountability mechanisms to Fujifilm’s life sciences and healthcare subsidiaries. The Committee will advise on complex ethical considerations that arise across research, product development, AI-enabled technologies, manufacturing, and commercialization.
“Patients, providers, and partners expect more than just innovation – they expect responsibility. The Bioethics Advisory Committee strengthens our governance, so ethical considerations are embedded from discovery through delivery,” said Yutaka Yamaguchi, Corporate Vice President and General Manager of Life Sciences Business Division, FUJIFILM Corporation and CEO of FUJIFILM Biosciences. “By combining diverse experts with leaders from our internal team, we’re raising the bar for transparency and accountability in how we innovate as a global life sciences leader.”
The Committee will include a range of Fujifilm subject matter experts from various areas and independent experts in the areas of bioethics, medicine, law, compliance, and patient advocacy. The main purpose of the Committee will be to serve as an advisory body to Fujifilm’s subsidiary businesses and regional teams to address complex ethical questions relevant to the fields of biological research, science, and medicine. The Committee’s perspectives on emerging issues and scientific trends — such as AI, human biological specimens, gene editing, stem cell research, and patient involvement — are aimed to help Fujifilm’s life science businesses prioritize the interests of patients, researchers, and the public.
“Fujifilm’s pledge to be ‘Partners for Life’ reflects its commitment to protect the integrity of clinical outcomes and ensure life-changing therapies are developed and delivered responsibly,” said Alta Charo, JD, professor emerita of law and bioethics at the University of Wisconsin at Madison and Committee Chairperson. “Ethics is not a box to check; it is a promise to patients. Our goal is to anticipate ethical risks early and translate principles into practical, operational guidance.”
As part of its commitment to transparency, the Committee will publish policies that address bioethical dilemmas to enable our life sciences and healthcare companies to make sound decisions as science continues to evolve.
“We are bringing in top-tier leaders in the field of bioethics – individuals who currently serve or served on the bioethics boards of other life sciences institutions and are widely recognized in the industry for their deep expertise and thought leadership,” said Toshihisa Iida, Director, Corporate Vice President, General Manager of the Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, and Chairman, FUJIFILM Biotechnologies. “This framework is a clear example of how we live out Fujifilm’s ‘Partners for Life’ commitment: by building trust worldwide and ensuring that innovation is always matched with integrity.”
The Committee’s inaugural meeting will convene in December 2025.
A full list of committee members is available in the appendix below.